Extrapolation of Efficacy in Pediatric Drug Development and Evidence-based Medicine: Progress and Lessons Learned
Tóm tắt
“Complete Extrapolation” of efficacy from adult or other pediatric data, to the pediatric population, is an important scientific tool that reduces the need for pediatric efficacy trials. Dose finding and safety studies in pediatrics are still needed. “No Extrapolation” requires 2 pediatric efficacy trials. “Partial Extrapolation” eliminates the need to conduct 2 pediatric efficacy trials; 1 efficacy or exposure/response study may be sufficient. We examined pediatric extrapolation from 2009 to 2014 evaluating any changes in extrapolation assumptions and the causes for these changes since a prior analysis published in 2011. We reviewed all 157 products with 388 pediatric studies submitted to the FDA from 2009 through 2014. We assessed whether efficacy was extrapolated from adult or other pediatric data and categorized extrapolation as Complete, Partial, or No, and identified the reasons for the changes. Partial extrapolation decreased, whereas use of No and Complete extrapolation noticeably increased. Complete, Partial, or No extrapolations changed from 14%, 68%, and 18% in the 2011 study to 34%, 29%, and 37% respectively in the current study. The changes were mostly due to a better understanding of pediatric pathophysiology, why trials have failed, and improved endpoints. Evolving science and data obtained from clinical trials increases the certainty of extrapolation assumptions and drives decisions to utilize extrapolation. Lessons learned from the conduct of these trials are critical to improving evidence-based medicine. Extrapolation of Efficacy is a powerful scientific tool that streamlines pediatric product development. Increased knowledge and evolving science inform utilization of this tool.
Tài liệu tham khảo
Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307:1914–1915.
Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011;128: e1242–e1249.
FDA. Specific requirements on content and format of labeling for human prescription drugs; revision of “pediatric use” subsection in the labeling; final rule. Fed Regist. 1994;59:64240. https://www.federalregister.gov/documents/1994/12/13/94-30238/specific-requirements-on-content-and-format-of-labeling-for-human-prescription-drugs-revision-of.
The Pediatric Research Equity Act 2007. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf.
Best Pharmaceuticals for Children Act 2007. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf.
FDA. Guidance for industry: the content and format for pediatric use supplements. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071957.pdf. FDA. Published 1996.
FDA. Guidance for industry: pediatric oncology studies in response to a written request (Draft Guidance). https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071976.pdf. Published 2000.
Christensen ML, Franklin BE, Momper JD, Reed MD. Pediatric drug development programs for type 2 diabetes: a review. J Clin Pharmacol. 2015;55:731–738.
Holmes GL. Data related to disease similarity—a case study: PEACE initiative in pediatric epilepsy. Paper presented at: Quantitative Assessment of Assumptions to Support Extrapolation of Efficacy in Pediatrics (FDA/University of Maryland CERSI Workshop); June 1, 2016; Silver Spring, MD. http://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pedsextrapolation/holmes-presentation-notes.pdf.
Mehrotra S. Quantitative analysis to support full extrapolation of efficacy in children for partial onset seizures in adjunctive setting: FDA-PEACE initiative. Paper presented at: Quantitative Assessment of Assumptions to Support Extrapolation of Efficacy in Pediatrics (FDA/University of Maryland CERSI Workshop); June 1, 2016; Silver Spring, MD. http://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pedsextrapolation/mehrotra-presentation-notes.pdf.
Sheridan P. Pediatric extrapolation of efficacy in partial seizures: regulatory perspective. Paper presented at: Quantitative Assessment of Assumptions to Support Extrapolation of Efficacy in Pediatrics (FDA/University of Maryland CERSI Workshop); June 1, 2016; Silver Spring, MD. http://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pedsextrapolation/sheridan-presentation-notes.pdf.
Lightdale JR, Gremse DA. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131:e1684–e1695.
Orenstein SR, Izadnia F, Khan S. Gastroesophageal reflux disease in children. Gastroenterol Clin North Am. 1999;28:947–969.
Vandenplas Y, Belli D, Benhamou P, et al. A critical appraisal of current management practices for infant regurgitation—recommendations of a working party. Eur J Pediatr. 1997;156:343–357.
Vandenplas Y, Hauser B. An updated review on gastro-esophageal reflux in pediatrics. Expert Rev Gastroenterol Hepatol. 2015;9:1511–1521.
Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498–547.
Bussieres JF, Therrien R, Hamel P, Barret P, Prot-Labarthe S. Retrospective cohort study of 163 pediatric glaucoma patients. Can J Ophthalmol. 2009;44:323–327.
Papadopoulos M, Cable N, Rahi J, Khaw PT. The British Infantile and Childhood Glaucoma (BIG) Eye Study. Invest Ophthalmol Vis Sci. 2007;48:4100–4106.
Plager DA, Whitson JT, Netland PA, et al. Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. J AAPOS. 2009;13:384–390.
Fung DS, Roensch MA, Kooner KS, Cavanagh HD, Whitson JT. Epidemiology and characteristics of childhood glaucoma: results from the Dallas Glaucoma Registry. Clin Ophthalmol. 2013;7:1739–1746.
Whitson JT, Roarty JD, Vijaya L, et al. Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. J AAPOS. 2008;12:239–246.e3.
Elder DA, Herbers PM, Weis T, Standiford D, Woo JG, D’Alessio DA. Beta-cell dysfunction in adolescents and adults with newly diagnosed type 2 diabetes mellitus. J Pediatr. 2012;160:904–910.
Gungor N, Arslanian S. Progressive beta cell failure in type 2 diabetes mellitus of youth. J Pediatr. 2004;144:656–659.
Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90:493–500.
Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab. 2003;88:1417–1427.
Elder DA, Hornung LN, Herbers PM, Prigeon R, Woo JG, D’Alessio DA. Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. J Pediatr. 2015;166:672–678.
Gungor N, Saad R, Janosky J, Arslanian S. Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr. 2004;144:47–55.
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787–794.
CERSI. Quantitative Assessment of Assumptions to Support Extrapolation of Efficacy in Pediatrics at http://www.pharmacy.umaryland.edu/centers/cersievents/pedsextrapolation/. [Public Workshop]. Published 2016.